Facial plast Surg 2017; 33(05): 537-544
DOI: 10.1055/s-0037-1605599
Rapid Communication
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Facial Volume Restoration with Permanent Dermal Filler (Artecoll-4) in Chinese Women

Dong Li
Department of Plastic and Aesthetic Surgery, Peking University Third Hospital, Beijing, China
Sheng-Kang Luo
Department of Plastic and Cosmetic Surgery, Guangdong No. 2 Provincial People's Hospital, Guangzhou, China
Yi-Chao Wang
Department of Burns and Plastic Surgery, Peking University First Hospital, Beijing, China
Gottfried Lemperle
Division of Plastic Surgery, University of California, San Diego, California
› Author Affiliations
Further Information

Publication History

Publication Date:
29 September 2017 (online)


Artecoll is the only permanent dermal filler to be approved by the European Union and China Food and Drug Administration, and has been used worldwide since 1994 in approximately 400,000 patients. Since 2002, Artecoll-4 has also been injected in China in more than 42,000 patients in more than 100 hospitals, primarily for beauty refinement in younger patients and for rejuvenation of the aging face. Artecoll-4 consists of polymethylmethacrylate (PMMA) microspheres (20% by volume) 40 µm in diameter, suspended in 3.5% bovine collagen solution and 0.3% lidocaine. The collagen carrier is absorbed rather early after injection and is completely replaced by the patient's own connective tissue within the first 3 months. Thus, in contrast to all other fillers, Artecoll-4 becomes the patient's own tissue, and it is a “living implant.” In this study, a total of 10,725 patients were treated in 25 Chinese cosmetic hospitals between 2007 and 2012. Optimal injection techniques, efficiency and lasting duration, complications, safety, outcome, and statistical results are discussed. The data support the safety and efficiency of large volumes of Artecoll-4 (5–10 mL) injected deep into the faces of Chinese women, who seek to have a smooth oval face without indentations. No foreign body granulomas have been reported since the recommendation for strict epiperiosteal injections. Level of evidence is Level IV, multiple center study.